Health

  • February 24, 2026

    Ariz. Bill To Limit 'No Surprises' Arbitration Offers Put On Hold

    A powerful Arizona state lawmaker this week agreed to pause his proposal to establish limits on how much medical providers can seek under the No Surprises Act arbitration system, saying the legislation needs more work and he'll bring it back next year.

  • February 24, 2026

    2nd Circ. Axes Diagnostic Test Fraud Suit Against Siemens

    The Second Circuit on Tuesday affirmed a lower court's dismissal of a lawsuit accusing Siemens of defrauding the government, saying there's no example of a single diagnostic medical test rendered unreliable from the company's alleged shipping practices.

  • February 24, 2026

    Feds' White Collar Crime Enforcement 'Retreat' Raises Alarms

    Money laundering-related fines and tax fraud investigations plummeted last year as President Donald Trump shifted federal agents away from combating financial crime to focus on the immigration crackdown, according to recent reports that have raised alarms among experts about the state of white collar enforcement in the U.S.

  • February 24, 2026

    Mallinckrodt's Ch. 11 Blocks Antitrust Payouts, Judge Rules

    A Connecticut federal judge has ruled that drugmaker Mallinckrodt PLC shrugged off monetary claims brought by states in a sprawling generic drug antitrust enforcement action when the company emerged from bankruptcy in 2022.

  • February 24, 2026

    United Wants Partial Fraud Suit Win Against Billing Co.

    TeamHealth has been submitting fraudulent claims to get UnitedHealthcare to overpay it by more than $100 million, the insurer argued as it asked a Tennessee federal judge to grant it a partial early win in its suit against the emergency room staffing and billing company.

  • February 24, 2026

    Biotech Co. Moves To Dismiss LSD Trade Secret Suit

    A biotechnology company accused of having lifted trade secrets regarding clinical trials of potential LSD treatments for psychiatric disorders asked a Delaware federal judge Monday to dismiss or narrow the suit, which it says was brought by a "disgruntled former vendor."

  • February 24, 2026

    Headache-Focused Biotech Raises $130M In Series A Round

    Headache disorder-focused biotech Slate Medicines Inc., advised by Cooley LLP, on Tuesday revealed that it wrapped a Series A funding round with $130 million in tow.

  • February 24, 2026

    Clark Hill Faces DQ Bid In NJ Health Noncompete Fight

    Clark Hill PLC is facing a disqualification bid in New Jersey federal court from a health consulting company arguing the firm is unethically seeking to take sides in a dispute between two codefendants.

  • February 24, 2026

    AstraZeneca Drug Price Challenge Falls Short In Hawaii

    A federal judge in Hawaii temporarily upheld the state's law that prevents drug manufacturers from blocking safety-net hospitals from contracting with an unlimited number of outside pharmacies to dispense discounted prescription drugs under the 340B Drug Discount Program. 

  • February 24, 2026

    Medtronic's Diabetes Spinoff MiniMed Seeks $742M IPO

    Diabetes-focused MiniMed Group on Tuesday launched plans to go public by raising an estimated $742 million in an initial public offering, a move that is part of a previously announced plan by parent company Medtronic to spin its diabetes business into an independent public company.

  • February 24, 2026

    8th Circ. Won't Revive Iowa Pathology Lab's Antitrust Claims

    The Eighth Circuit has affirmed a lower court ruling that tossed a case accusing Iowa Pathology Associates of monopolizing pathology services in central Iowa, finding the rival never explained why doctors can't use labs that are located further away.

  • February 23, 2026

    FedEx, Bausch, Other Cos. Join Race For Tariff Refunds

    FedEx, Bausch & Lomb and L'Oreal are among the companies that raced to the U.S. Court of International Trade on Monday seeking full refunds of the trade duties they paid as a result of the 2025 tariffs that President Donald Trump illegally imposed under the International Emergency Economic Powers Act.

  • February 23, 2026

    DC Circ. Talks Sharks, Moats In Vertex HHS Kickback Appeal

    Sharks and moats were top of mind Monday morning for one judge on the D.C. Circuit, as gene therapy drugmaker Vertex Pharmaceuticals attempted to convince the court that its fertility preservation program does not violate the Anti-Kickback Statute.

  • February 23, 2026

    Zynex Faces Securities Suit Following Arrest Of Former Execs

    After being arrested last month on charges of securities fraud and conspiracy, the former CEO and ex-chief compliance officer of bankrupt medical device maker Zynex have been hit with a securities class action that alleges they and others caused the company to engage in fraudulent billing practices that inflated its stock price and led to investor losses once the truth came to light.

  • February 23, 2026

    Fla. Hospital Blames UnitedHealth In Cyberattack Suit

    A Florida hospital sued UnitedHealth Group Inc. and several subsidiaries in Georgia federal court on Friday, saying they didn't live up to their contractual obligations when a 2024 cyberattack left the hospital unable to process payments for weeks.

  • February 23, 2026

    Philly-Area Fertility Clinic Settles Patient's Acid Burn Suit

    A woman who sued a fertility clinic for allegedly mistakenly injecting her uterine cavity with acid, which she said caused her to suffer second-degree burns, has settled her lawsuit against the clinic for an undisclosed amount.

  • February 23, 2026

    Disability Group Says Mich. Agency Isn't Honoring Judgment

    A disability advocacy group asked a Michigan federal judge on Monday to order a county mental health agency to explain why it should not be held in civil contempt, saying the agency refused to follow new Medicaid budgeting rules that were adopted as part of a court-approved settlement.

  • February 23, 2026

    SEC Says PPE Distributor Fabricated Pandemic-Era Deal

    The U.S. Securities and Exchange Commission filed a suit Monday accusing the CEO and consultant of a consumer goods company of artificially inflating the company's share price by nearly 200% by disseminating a false press release touting $10 million in orders for health supplies at the beginning of the COVID-19 pandemic.

  • February 23, 2026

    Asthma Biotech Generate Biomedicines Eyes $400M IPO

    Asthma-focused biotech firm Generate Biomedicines on Monday filed plans with U.S. regulators to raise around $400 million in its initial public offering led by Goodwin Procter LLP and Latham & Watkins LLP.

  • February 23, 2026

    Analyst Who Claimed She Was Fired For Needing Sleep Settles

    A New Jersey woman who claimed she was fired by Centerview Partners after disclosing she needed consistent sleep to manage a health disorder settled her case against the investment bank ahead of a jury trial in New York federal court, the bank said Monday.

  • February 23, 2026

    Pittsburgh Law Firm Hit With Class Claims Over Data Breach

    A Pittsburgh-based law firm has been hit with proposed class claims alleging it failed to protect clients' private information, which was compromised by a data breach in May.

  • February 23, 2026

    NJ Watchdog Takes File Fight In Hospital Row To 3rd Circ.

    A New Jersey watchdog will take its bid to shield investigative files from discovery in a hospital's antitrust suit to the Third Circuit, according to a court notice.

  • February 23, 2026

    Hims & Hers Misleads With GLP-1 Claims In Ads, Court Told

    A class of GLP-1 patients claim that telehealth company Hims & Hers falsely advertised its compounded injections as made with "the same active ingredient" as weight loss drugs Ozempic and Wegovy despite containing other key ingredients, according to a suit filed in Illinois federal court. 

  • February 23, 2026

    Ropes, Wilson Sonsini Guide Gilead's $7.8B Arcellx Buy

    Gilead Sciences Inc. announced Monday that it has agreed to acquire clinical-stage biotechnology company Arcellx Inc. for $115 per share in cash plus one contingent value right worth $5 per share, reflecting an implied equity value of $7.8 billion.

  • February 23, 2026

    Kirkland, Jones Day Build $1.1B Hospice Take-Private Deal

    Home health and hospice provider Enhabit Inc., advised by Jones Day, on Monday unveiled plans to go private following a sale to middle market private equity firm Kinderhook Industries LLC, led by Kirkland & Ellis LLP, in an all-cash deal valued at roughly $1.1 billion.

Expert Analysis

  • Series

    Muay Thai Makes Me A Better Lawyer

    Author Photo

    Muay Thai kickboxing has taught me that in order to win, one must stick to one's game plan and adapt under pressure, just as when facing challenges by opposing counsel or judges, says Mark Schork at Feldman Shepherd.

  • The Next Pressure Point In Digital Health: Informed Consent

    Author Photo

    Two new federal digital health initiatives will usher in a new era where virtual care, software-enabled devices and home-based monitoring are integrated into care and reimbursement models, with the impact of shifting rules and opportunities felt most immediately in the context of informed consent, says Kimberly Chew at Husch Blackwell.

  • Series

    Law School's Missed Lessons: Intentional Career-Building

    Author Photo

    A successful legal career is built through intention: understanding expectations, assessing strengths honestly and proactively seeking opportunities to grow and cultivating relationships that support your development, say Erika Drous and Hillary Mann at Morrison Foerster.

  • 4 Trends Shaping Drug And Medical Device Law For 2026

    Author Photo

    2025 saw some significant legal developments with potential impact for drug and device manufacturers, ranging from growing skepticism in science and regulatory entities to new regulation of artificial intelligence, say attorneys at Faegre Drinker.

  • Key Trends In Healthcare Antitrust In 2025

    Author Photo

    The healthcare industry braced for significant antitrust enforcement shifts last year driven by a change in administration, and understanding the implications of these trends is critical for healthcare organizations' risk management and strategic decision-making in the year ahead, say attorneys at Michael Best.

  • The 5 Most Important Bid Protest Decisions Of 2025

    Author Photo

    In a shifting bid protest landscape, five decisions in 2025 from the Federal Circuit, the U.S. Court of Federal Claims and the U.S. Government Accountability Office that addressed bedrock questions about jurisdictional reach and the breadth of agency discretion are likely to have a lasting impact, say attorneys at Bradley Arant.

  • Food Industry Braces For MAHA And Other Challenges In 2026

    Author Photo

    After the Make America Healthy Again movement kept the U.S. Food and Drug Administration under pressure in 2025, actions in the food safety space are likely to continue this year, including updated Supplemental Nutrition Assistance Program dietary guidelines and processed food definitions, say attorneys at Wiley.

  • Preparing For Congressional Investigations In A Midterm Year

    Author Photo

    2026 will be a consequential year for congressional oversight as the upcoming midterm elections may yield bolder investigations and more aggressive state attorneys general coalitions, so companies should consider adopting risk management measures to get ahead of potential changes, say attorneys at Morgan Lewis.

  • A Meaningful Shift In FDA's Biosimilarity Analysis

    Author Photo

    The U.S. Food and Drug Administration's potential pivot away from routinely requiring comparative efficacy studies for interchangeable biosimilar applications would not lower regulatory standards, but instead allow applicants to allocate resources toward establishing more probative evidence, says Theodore Thompson at Stinson.

  • Employment Immigration Trends And Challenges For 2026

    Author Photo

    U.S. companies competing for global talent should brace for a turbulent 2026, with greater compliance burdens, higher costs and the probability of workforce disruptions at every stage of the immigration process, from visa petitions to work authorization renewals, say attorneys at Duane Morris.

  • Top 5 Antitrust Issues For In-House Counsel To Watch In 2026

    Author Photo

    With Trump administration enforcement policy having largely taken shape last year, antitrust issues that in-house counsel should have on the radar range from scrutiny of technology-assisted pricing to the return of merger remedies, say attorneys at Squire Patton.

  • 4 Developments That Defined The 2025 Ethics Landscape

    Author Photo

    The legal profession spent 2025 at the edge of its ethical comfort zone as courts, firms and regulators confronted how fast-moving technologies and new business models collide with long-standing professional duties, signaling that the profession is entering a period of sustained disruption that will continue into 2026, says Hilary Gerzhoy at HWG Law.

  • Navigating AI In The Legal Industry

    Author Photo

    As artificial intelligence becomes an increasingly integral part of legal practice, Law360 guest commentary this year examined evolving ethical obligations, how the plaintiffs bar is using AI to level the playing field against corporate defense teams, and the attendant risks of adoption.

  • How Fractional GCs Can Manage Risks Of Engagement

    Author Photo

    As more organizations eliminate their in-house legal departments in favor of outsourcing legal work, fractional general counsel roles offer practitioners an engaging and flexible way to practice at a high level, but they can also present legal, ethical and operational risks that must be proactively managed, say attorneys at Boies Schiller.

  • Health, Legal Employers Face Unique Online Speech Hurdles

    Author Photo

    Employers in the legal and healthcare industries must consider distinctive ethical obligations and professional requirements when disciplining employees for social media posts, while anticipating an area of the law in flux as courts seek to balance speech rights and the workplace function, say attorneys at FordHarrison.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.